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Autoregulationst-transcriptional regulators of gene expression that play a role in viral infection.
We have developed a method to identify viral-encoded miRNAs from viruses in which abundant amounts of
infected material is limiting. We show that Merkel Cell Polyomavirus (MCV), a recently identiﬁed human
virus associated with cancer, encodes a miRNA. This miRNA is expressed from the late strand, lies antisense
to the early transcripts and negatively regulates expression of chimeric reporters containing a portion of the
early transcripts. Interestingly, different viral isolates have sequence polymorphisms in the pre-miRNA region
that result in amino acids substitutions but fully preserve the processing and activity of the miRNAs.
© 2008 Elsevier Inc. All rights reserved.IntroductionmicroRNAs (miRNAs) are post-transcriptional regulators of gene
expression that play a role in numerous and diverse cellular processes
including viral infection (reviewed in Gottwein and Cullen, 2008; Grey
et al., 2008; Nair and Zavolan, 2006; Pfeffer, 2008; Samols and Renne,
2006; Sarnow et al., 2006; Sullivan, 2008; Sullivan and Ganem, 2005).
Over 120 viral miRNAs have been described from divergent families of
DNA viruses. A functional understanding of the majority of viral
miRNAs remains incomplete or unknown, however recent studies
clearly demonstrate that some viral miRNAs will regulate host gene
expression, viral gene expression, or both. Viral miRNAs that regulate
host transcripts with relevance to tumorigenesis and immune evasion
have been described. In addition, diverse viruses, including an
ascovirus (Hussain, Taft, and Asgari, 2008), and several members of
the Herpesviridae and Polyomaviridae have been shown to encode
miRNAs that autoregulate viral gene expression (Gottwein and Cullen,
2008; Pfeffer, 2008). It has been hypothesized that viral miRNA-
mediated autoregulation of gene expression contributes to regulation
of the virus lifecycle including the maintenance of latency and
activation of lytic replication (Umbach et al., 2008) — the proper
balance of which is key to immune evasion strategies. Therefore,
proper functioning of autoregulatory miRNAs likely profoundly affects
the ﬁtness of some viruses during natural infection in vivo. Thus,
combined with the recent successes in rationally-designed anti-
miRNA inhibitors (Elmen et al., 2008; Krutzfeldt et al., 2005), theseSullivan).
l rights reserved.observations suggest viral miRNAs might make worthy anti-viral drug
targets. Members of the Polyomaviridae include the model laboratory
tumor viruses murine polyomavirus (MuPyV) and Simian Virus 40
(SV40), and the human pathogens BK virus (BKV) and JC virus (JCV).
We have previously shown that multiple members of the Polyomavi-
ridae, including SV40, JCV, BKV, and MuPyV encode miRNAs that
autoregulate early gene expression at late times of infection (Seo et al.,
2008; Sullivan et al., 2005, 2006; Sullivan et al., submitted for
publication). Recently, three new human polyomaviruses have been
described, including KI virus (KIV), WU virus (WUV) and Merkel Cell
Polyomavirus (MCV) (Allander et al., 2007; Feng et al., 2008; Gaynor
et al., 2007). All three were discovered using new molecular-based
technologies. It seems clear from these and other related technologies
that we are in for an avalanche of new virus discoveries. Many of these
viruses are being discovered faster than in vitro culture systems can be
developed. Here we present a method for identifying viral-encoded
miRNAs that does not require an experimental infectious system. We
show that MCV, a likely etiologic agent of human cancer, encodes a
miRNA on the late strand that (similar to other reported Polyomaviral
miRNAs) has the potential to autoregulate early gene expression.
These results further emphasize an important role for miRNAs in
Polyomaviral biology and suggest a possible target for future
therapeutic strategies.
Results
We set out to develop an experimental strategy to identify viral-
encoded miRNAs that does not require abundant amounts of infected
material.We chose to examinewhetherMCV encoded amiRNA for the
184 G.J. Seo et al. / Virology 383 (2009) 183–187following reasons: ﬁrst, MCV was only recently discovered and so far
no experimental infectious systems have been reported. Second, MCV
is linked to human cancer and is likely a bona ﬁde human pathogen,
suggesting a possible need to develop anti-viral therapeutic targets.
Third, because we have previously shown that divergent members of
the polyomavirus family (including the SV40-like polyomaviruses and
MuPyV) encode miRNAs to autoregulate early gene expression, it
seemed probable that other members of the family, including MCV,
would also encode miRNAs of similar function.
Our strategy is to computationally predict likely candidate pre-
microRNAs (pre-miRNAs) and then to clone them, including ﬂanking
sequence, into a heterologous expression vector under control of the
cytomegalovirus major early promoter (CMV). These plasmids are
then transiently transfected and screened for bona ﬁde miRNA
expression using several criteria including: Northern blot analysis,
cloning and sequencing, and activity in chimeric target reporter
assays. We ran the sequence of both published MCV isolates in the
viral miRNA prediction algorithm Vmir (Grundhoff et al., 2006;
Sullivan and Grundhoff, 2007; Sullivan et al., 2005). A relatively
stringent arbitrary cutoff score of 200 was used and we focused on
transcripts of the late orientation where all other Polyomaviral
miRNAs have so far been identiﬁed. Only two candidates met these
criteria (Fig. 1A). One candidate, MR62 was found near the origin of
replication and was predicted for both the MCC339 and MCC350
isolate genomes. However, this candidate was discarded because this
region of the genome produced false positive candidates from several
other members of the Polyomaviridae (CSS, unpublished observa-
tions). The other candidate, MR17, was the top scoring Vmir prediction
for MCC339. However, due to three nucleotide substitutions in the
pre-miRNA hairpin region (Fig. 1B), MR17 was ranked only the sixth
best candidate for MCC350. We nonetheless pursued candidate MR17
(although it shared no sequence identity with any other known pre-
miRNAs of viral or host origin), because it did however, map to a
region of the genomewe have previously shown encodes a pre-miRNA
in MuPyV (Sullivan et al., submitted for publication).Fig. 1. Vmir predictions for MCV pre-miRNAs. (A) Candidate pre-miRNAs are indicated for bo
bothMCC339 andMCC350 (referred to as MR17 in the text) is markedwith a red circle. (B) Th
between MCC 350 and MCC 339 are shown (bold). The ﬁne-mapped sequences of the 5p (rA portion of the genome including candidate MR17 and ﬂanking
regions was cloned from either the MCC339 or MCC350 isolates into
an expression vector. The resulting plasmids were then transfected
into 293T cells. Total RNA was harvested and Northern blot analysis
was conducted with the probes described in Fig. 2A. The 5p probe
detected 2 bands from RNA harvested from cells transfected with
either the MCC339 or MCC350 expression vector. The slower
migrating band is approximately 65 nucleotides (consistent with it
being a pre-miRNA), and the faster migrating band is approximately
22 nucleotides—exactly where a bona ﬁdemiRNA should migrate. The
3p probe detected the slower ∼65 nucleotide band and low amounts
of a ∼22 nucleotide band. Importantly, no speciﬁc bands were
detected from RNA harvested from cells transfected with a negative
control vector in which a 300 nucleotide portion of MCC350
(containing the pre-miRNA and ﬂanking regions) was deleted. In
addition, a control probe directed against the terminal “loop” portion
of the predicted pre-miRNA hairpin, which should not be stabilized by
the downstream miRNA processing and effector machinery, only
recognized the ∼65 nucleotide band. These results rule out non-
speciﬁc RNA degradation as a source of the 22 nucleotide band
detected with the 5p probe. Combined, these results strongly suggest
that multiple isolates of MCV encode a pre-miRNA in the late
orientation, of which both the 5p and 3p arms of the hairpin are
processed into miRNAs. In accordance with the established miRBase
precedence (Grifﬁths-Jones, 2006), we have named these miRNAs
“MCV-mir-M1 5p” and “MCV-mir-M1 3p”.
To map the derivative miRNAs with more precisionwe generated a
small RNA library from cells expressing the MCC350 miRNAs. Small
RNAs were gel puriﬁed and ligated to linkers, and reverse transcrip-
tion was performed to generate a cDNA library. PCR was then
conducted with primers speciﬁc to each arm of the Vmir predicted
pre-miRNA hairpin. Using this strategy we were able to individually
map the 3′ and 5′ ends of both the 3p and 5p miRNAs. Notably, the
miRNA sequences we mapped from the MCC350 isolate are com-
pletely conserved with the MCC339 isolate. (Fig. 1B).th the MCC 339 and MCC 350 isolates (diamonds). The candidate that scored positive in
e secondary structure predictions for MCV precursors are shown. The polymorphic sites
ed) and 3p miRNAs (blue) are indicated.
Fig. 2. TheMerkel Cell Polyomavirus isolatesMCC 339 andMCV 350 encodesmiRNAs. (A) Diagram of probes used. Each samplewas assayedwith a probe that detects the 5p or 3p arm
or terminal loop portion of the pre-miRNA. (B–D) Northern blot analysis for the MCV miRNAs. RNA harvested from cells transfected with the mock, negative control ΔMCV miRNA,
the MCC339 or MCC350 miRNA expression vectors was analyzed with the indicated probes. Ethidium bromide staining of the low molecular weight RNA is shown as a loading
control. Bands corresponding to the 5p and 3p miRNAs (black arrow) or the pre-miRNA (gray arrow) are indicated.
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active miRNA. miRNAs are initially transcribed as long precursor
molecules that contain a characteristic ∼80–100 nucleotide hairpin
secondary structure. This hairpin is recognized and excised by the
nuclearmicroprocessormulti-protein complex resulting in an ∼53–80
nucleotide precursor miRNA (pre-miRNA) (reviewed in Gottwein and
Cullen, 2008). The pre-miRNA is further processed by the cytoplasmic,
RNAse III-like endonuclease Dicer into a transient double-stranded
∼22 nucleotide intermediate. Eventually, a portion of a single “arm” of
the pre-miRNA hairpin is incorporated in a stable manner into the
multi-protein RNA Induced Silencing Complex (RISC). RISC-bound
miRNAs can then bind to target mRNAs with perfect or imperfect
complementarity, typically resulting in cleavage or translational
repression of the targeted mRNA. We have previously shown that
multiple members of the Polyomaviridae encode miRNAs that are
active within RISC to direct the cleavage of the complementary early
strand RNAs late during infection (Seo et al., 2008; Sullivan, 2008;
Sullivan et al., 2005, 2006; Sullivan et al., submitted for publication).
Given that MCV-mir-M1 is encoded on the late strand, antisense to the
early transcripts (Figs. 3A, B), we predicted that it would direct the
cleavage of the early transcripts. To test this hypothesis, we
engineered a chimeric luciferase reporter construct, in which a 300
nucleotide portion of the early transcripts (including theMCV-mir-M1
complementary and ﬂanking regions) was cloned into the 3′ UTR.
Co-transfection of this reporter with either the MCC339 or MCC350
MCV-mir-M1 expression plasmids results in a dramatic reduction in
luciferase activity (Fig. 3C, left panel). Co-transfections of vector alone,
an irrelevant miRNA (JCV), or a vector encoding MCC350 with the
miRNA region deleted had no effect on this reporter (Fig. 3C, left
panel) arguing that the effect we observe is speciﬁc to the MCV
miRNAs. Importantly, no effect of the MCV miRNAs was detected
when they were co-transfected with a control reporter plasmid that
lacked complementary sites to MCV-mir-M1 (Fig. 3C, right panel).
From these results, two inferences can be made. First, MCV-mir-M1 is
fully active within RISC, lending further support as to the authenticity
of this miRNA. Second, MCV-mir-M1 functions to direct cleavage of
the early RNAs during MCV infection.
Discussion
The post-genomic era has ushered in several new virus discovery
techniques that will likely provide a windfall of new pathogens in the
near future. Many of these viruses will not have a readily availableexperimental systemmaking developing and testing anti-viral drugs a
challenge. We propose that one useful strategy will be to identify
virus-encoded miRNAs and utilize existing successful antisense anti-
miRNA drug strategies (Elmen et al., 2008; Krutzfeldt et al., 2005) to
develop potential therapeutics. A ﬁrst step to realizing this goal is to
develop methods to identify miRNAs encoded by such pathogens. In
this work, we describe such a method and prove its utility on the
recently described polyomavirus MCV. We show that two different
strains of MCV encode the miRNA despite having a difference of 3
nucleotide substitutions in the pre-miRNA hairpin. Interestingly, these
substitutions result in 2 non-conservative amino acid substitutions in
the Large T antigen protein that is encoded on the early strand
(Fig. 3B). However, these changes do not signiﬁcantly alter the
predicted pre-miRNA hairpin secondary structures on the late strand
(Fig. 1B) and the pre-miRNAs from both the MCC339 and MCC350
isolates have similar processing efﬁciencies (Fig. 2). Furthermore, the
derivative miRNAs from both the MCC350 and MCC339 isolates have
similar activities in directing the cleavage of the early transcript
reporter (Fig. 3C). These results suggest evolutionary pressure exists
for MCV to maintain expression of the miRNAs.
We used stringent criteria to conclude that MCV-mir-M1 is a bona
ﬁde miRNA. The miRNA we identiﬁed is detectable via Northern blot
analysis (Fig. 2) and is active at directing the inhibition of reporter
gene expression, most likely through a RISC-mediated mechanism
(Fig. 3C). Furthermore, ﬁne mapping studies of the MCV-mir-M1 and
its cognate⁎3P sequence (the strand that is less efﬁciently incorpo-
rated into RISC) results in a predicted duplex secondary structure
with 2–3 nucleotide 3′ overhangs — a hallmark of both micro-
processor and Dicer processing. Combined, these results prove
MCV-mir-M1 is a bona ﬁde miRNA. A notable caveat to our approach
is the possibility that we have missed other possible bona ﬁde
miRNAs encoded by MCV. Indeed, Vmir predicted four candidates
that scored higher than MR17 in the MCC350 genome (Fig. 1A). While
Vmir is a useful starting point for identifying novel miRNAs in viral
genomes, a high Vmir score alone is relatively uninformative due to
the possibility of false positives. Therefore, ruling out the existence of
additional MCV miRNAs is not possible until exhaustive, saturated
small RNA cloning is performed on RNA obtained from all stages of
the virus lifecycle (e.g. persistent and lytic infection). Obviously,
these studies await the development of laboratory models of MCV
infection.
What is the function of the MCV miRNA? Two lines of reasoning
strongly suggest that MCV-mir-M1 functions to autoregulate early
Fig. 3. TheMCVmiRNAs downregulate early transcripts. (A) Map of MCV genomic organizationwith the location of the 5p and 3pmiRNA indicated with gray arrows. (B) Alignment of
the MCV early transcripts (5′–3′) with the complementary 5p miRNA indicated (3′–5′). Shown are the derived amino acids of MCV Large T Antigen that correspond to this region. (C)
Diagrams of the MCVmiRNA reporter construct (top, left) and control reporter (top, right) are shown. The vectors consist of a Renilla luciferase reporter with or without a single copy
of a 300 nucleotide region of the Large Tantigen early transcript (complementary to theMCVmiRNA) cloned into the 3′UTR. Cells were transfectedwith either reporter plus a plasmid
expressing vector alone, the MCV339 miRNA, the MCV350 miRNA, the JCV miRNA, or Δ MCV miRNA (a negative control MCV plasmid in which the pre-miRNA region has been
deleted). Fireﬂy luciferase was used as a transfection control and Renilla luciferase levels are plotted normalized relative to ﬁreﬂy luciferase levels.
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polyomavirus we have examined in detail, including the SV40-like
polyomaviruses (SV40, JCV and BKV) and MuPyV encode miRNAs at
late times of infection that direct the cleavage of early RNA acting to
autoregulate early protein levels at late times during infection (Seo
et al., 2008; Sullivan et al., 2005, 2006; Sullivan et al., submitted for
publication). The genomic location, antisense and complementary to
the early RNAs, supports a similar activity for MCV-mir-M1. Second,
we have demonstrated that a chimeric reporter containing a portion
of the early RNAs is speciﬁcally downregulated by expression of
MCV-mir-M1. Importantly, these results do not rule out a potential
additional function for MCV-mir-M1 in regulating a cellular target.
However, since MCV-mir-M1 shares no sequence identity with any of
the other known Polyomaviral miRNAs, it seems highly unlikely that
these miRNAs could bind to and regulate the same cellular target.
Thus, our results strongly suggest that a major function of the MCV
miRNA, similar to the other Polyomaviral miRNAs, will be to
autoregulate early gene expression at late times of infection.
Finally, the fact that theMCVmiRNA is likely only expressed during
lytic infection (when the late genes are expressed), limits the potential
utility of it as an anti-viral drug target. To date, MCV is associated with
tumorigenesis in cases where the viral genome has integrated into the
host genome in a stable fashion and is likely only competent to
express early gene products. It is currently unclear if any of these
tumors are undergoing active lytic infection. Nonetheless, blocking
the MCV miRNA function will do little to inhibit the tumorigenic
activity of T antigens that are expressed from the tumor genome.
However, as the MCV ﬁeld is brand new, it remains possible that lytic
infection may indeed one day be linked to pathogenesis, and in thatcase, MCV-mir-M1 is a plausible therapeutic target. Irrespective, our
study provides a proof of principle that viral miRNAs can rapidly be
identiﬁed in newly emerging pathogens.
Materials and methods
Computational prediction of MCV miRNA precursors and miRNA
Northern blot analysis
Vmir (Grundhoff et al., 2006; Sullivan and Grundhoff, 2007;
Sullivan et al., 2005) was used to predict candidate pre-miRNAs in the
MCV genome (the accession numbers are; MCC350: EU_375803,
MCC339:EU_375804). The candidates were cloned into pcDNA3.1-
puro, transiently transfected into human embryonic kidney cells
(HEK) 293T. Total RNA was harvested using an in house Trizol-like
reagent (2M Guanidinium Thiocyanate, 20mM Citrate buffer (PH 4.5),
5 Mm EDTA, 0.25% Sarkosyl, 48% saturated phenol (PH 4.5), 2.1%
isoamyl alcohol, 0.5% beta-mercaptoethanol, 0.1% 8-Hydroxyquioline,
0.0025% Coomassie blue) and Northern blot analysis was conducted as
previously described (Seo et al., 2008) using the following probes:
MCV5′ probe: GGAACCAGTGTACCTAGAAATTCTTCCAGAACGTA
MCV 3′ probe: AGACCACCAATTCAGGAAGAGAATCCAGCACACCCA
MCV loop: CACACCCAATGGAACCAGTGTAC
Small RNA library generations and ﬁne mapping of MCV miRNA
For ﬁne mapping of the MCV miRNA, a library was generated as
previously described (Seo et al., 2008). Brieﬂy, small RNA (10–40
187G.J. Seo et al. / Virology 383 (2009) 183–187nucleotides)washarvested from293Tcells transfectedwith theMCC350
miRNA expression plasmid. The small RNA was ligated and TA cloned
into PCR2.1. miRNA speciﬁc primers were used in a PCR reaction to map
both the 3′ and 5′ ends of the MCV miRNAs. The primers used were:
5′ linker forward primer: GTTGATCAGAGCCCAGGG;
3′ linker backward primer: ATTGATGGTGCCTACAG;
MCV 5p forward primer: AGTGTACCTAGAAATTCC
MCV 5p backward primer: GTTCTGGAAGAATTTCTA
MCV 3p forward primer: ATTCAGGAAGAGAATCCA
MCV3p backward primer: GTGTGCTGGATTCTCTTC
DNA constructs, transfection and luciferase assays
All DNA constructs were conﬁrmed by sequence analysis.
pCDNA3.1MCVmiRNA (MCC350), that expresses the MCV miRNAs,
was generated by subcloning into the Hind III/Xba I sites of
pCDNA3.1puro expression vector (Sullivan and Ganem, 2005). A
plasmid containing the entire MCV genome (kindly provided by Drs.
Chang and Moore, University of Pittsburgh) served as template to
subclone the region of the MCV genome containing the MCV pre-
miRNA as well as ∼1 Kb of ﬂanking regions. The resulting plasmid was
named “pcDNA3.1puroMCV350miRNA”. To construct the MCV339
miRNA expression vector, we conducted PCR mutagenesis using
pcDNA3.1puroMCV350miRNA as the template. As a negative control,
we engineered a deleted version of pcDNA3.1puroMCV350miRNA in
which 300 nucleotides of sequence, encompassing the pre-miRNA and
surrounding regions (nts 1017–1318 of the MCC350) was deleted. The
luciferase reporter assays were performed as previously described
(Seo et al., 2008) in HEK 293 cells. The reporter contains a single copy
of a 300 nucleotide sequence (1051–1350 nt positions from one of the
MCC genomes MCC350) corresponding to the complementary and
ﬂanking regions of the early transcripts. As a transfection control,
Renilla luciferase levels were normalized to a co-transfected ﬁreﬂy
luciferase reporter as previously described (Seo et al., 2008).
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